From: Subventricular zones: new key targets for glioblastoma treatment
 | SVZ without temporal horn (TH-) (n = 40) | SVZ with temporal horn (TH+) (n = 40) | p |
---|---|---|---|
Volume (cm3) | |||
 iSVZ | 5 (3.4–11) | 7.8 (4.9–15.5) | <0.001 |
 cSVZ | 5.5 (3.4–9.6) | 7.8 (5.6–15.1) | <0.001 |
 bSVZ | 10.6 (6.8–20.6) | 15 (11.8–30.6) | <0.001 |
Mean dose (Gy) | |||
 iSVZ | 51.3 (17.9–61.4) | 45.7 (22.9–61.5) | 0.298 |
 cSVZ | 15.4 (1.4–48.7) | 13.7 (1.3–41.5) | <0.001 |
 bSVZ | 35 (10.8–51.8) | 32.9 (14–46.4) | 0.830 |
V10Gy (%) | |||
 iSVZ | 100 (41.3–100) | 100 (55.4–100) | 0.637 |
 cSVZ | 83.4 (0–100) | 73.6 (0–100) | 0.074 |
 bSVZ | 90.9 (26.6–100) | 86.5 (36.5–100) | 0.264 |
V20Â Gy (%) | |||
 iSVZ | 96.8 (16.9–100) | 83.7 (29.8–100) | 0.256 |
 cSVZ | 11.6 (0–100) | 8.2 (0–92.1) | <0.001 |
 bSVZ | 52.6 (8.4–100) | 52.3 (15–96.1) | 0.444 |
V30Â Gy (%) | |||
 iSVZ | 87.6 (11.2–100) | 72.1 (20.8–100) | 0.392 |
 cSVZ | 0 (0–83.8) | 0 (0–66.6) | <0.001 |
 bSVZ | 48.5 (5.6–91.3) | 46.3 (10.4–76.5) | 0.861 |
V40Â Gy (%) | |||
 iSVZ | 79.7 (8.5–100) | 67 (17.5–100) | 0.357 |
 cSVZ | 0 (0–75.6) | 0 (0–62.2) | <0.001 |
 bSVZ | 43.5 (4.2–83.8) | 40.8 (8.8–72.7) | 0.883 |
V50Â Gy (%) | |||
 iSVZ | 69.1 (5.5–100) | 63.8 (14.2–100) | 0.451 |
 cSVZ | 0 (0–71.4) | 0 (0–56.4) | <0.001 |
 bSVZ | 37 (2.7–74.3) | 34.9 (7.1–66.3) | 0.798 |
V60Â Gy (%) | |||
 iSVZ | 28.7 (0–99.1) | 28.2 (0–99.7) | 0.687 |
 cSVZ | (0–53.9) | 0 (0–41.8) | 0.317 |
 bSVZ | 13.8 (0–60.6) | 14.2 (0–49.9) | 0.677 |